739 results on '"Sanacora, Gerard"'
Search Results
2. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders
3. Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol
4. Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study
5. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder
6. Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study
7. Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)
8. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia
9. Brain–phenotype models fail for individuals who defy sample stereotypes
10. Depression — Advanced Treatments for Treatment-Resistant Depression
11. 497. Prefrontal Cortex Astroglia Modulate Anhedonia-Like Behavior
12. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
13. A Novel Biomarker of Neuronal Glutamate Metabolism in Nonhuman Primates Using Localized 1H-Magnetic Resonance Spectroscopy: Development and Effects of BNC375, an α7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator
14. Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study
15. The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders
16. Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk
17. The Rapidly Shifting Ketamine Landscape in the US
18. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study
19. Cell-type specific modulation of NMDA receptors triggers antidepressant actions
20. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions
21. Intravenous arketamine for treatment-resistant depression: open-label pilot study
22. Early life stress and glutamate neurotransmission in major depressive disorder
23. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3
24. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression
25. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
26. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)
27. Candidate biomarkers in psychiatric disorders: state of the field
28. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression
29. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems
30. Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
31. Single-Dose Psilocybin Treatment for Major Depressive Disorder
32. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale
33. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD)
34. Correction to: Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS)
35. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression
36. Prefrontal Cortex Astroglia Modulate Anhedonia-like Behavior
37. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
38. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
39. Using Our Understanding of Stress-Related Effects on Glutamate Neurotransmission to Guide the Development of Novel Treatment Strategies
40. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies
41. Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study
42. Hippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysis
43. The Search for Rapid Acting Antidepressants: Research Synthesis and Perspectives
44. Contributors
45. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder
46. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects
47. Prophylactic efficacy of riluzole against anxiety- and depressive-like behaviors in two rodent stress models
48. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic
49. At-home ketamine; still a lot to learn
50. Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.